GLP-1 agonists are medications that help lower blood sugar levels and promote weight loss. There are many different types. And they're just one part of your treatment plan if you have Type 2 diabetes orobesity. Your healthcare provider can help you decide if they’re right for you. obesit...
Medications for diabetes comprise either GLP-1 receptor agonists, with short (one or two daily injections: Exenatide, Liraglutide, Lixisenatide) or long duration (one injection once weekly: extended-released Exenatide, Albiglutide, Dulaglutide, Taspoglutide); or oral compounds inhibiting dipeptidyl peptid...
[3] MadsbadS. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists[J]. Diabetes Obes Metab, 2016, 18( 4): 317- 332. [4] Tsapas A,Karagiannis T,Kakotrichi P,et al.Comparative efficacy of glucose-lowering medicatio...
Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet ...
Medications for diabetes comprise either GLP-1 receptor agonists, with short (one or two daily injections: Exenatide, Liraglutide, Lixisenatide) or long duration (one injection once weekly: extended-released Exenatide, Albiglutide, Dulaglutide, Taspoglutide); or oral compounds inhibiting dipeptidyl peptid...
GLP-1受体激动剂(GLP-1 receptor agonists),包括司美格鲁肽和替尔泊肽等,已被证实能够降低肝脏、肾脏和心脏的炎症反应。更令人惊喜的是,这些药物似乎能够减轻大脑中的炎症,这为利用化合物治疗帕金森和阿尔茨海默病提供了新思路。最近的一篇综述论文列出了多项正在探索这些药物作为这两种疾病疗法的临床试验。
medications is currently hindered by many unanswered questions, ranging from how best to select the optimal patients for treatment to their long-term effects to how to manage their costs. Among these is an increasingly urgent concern about the coverage and optimal treatment dura...
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. However, their effectiveness and risks have not yet been systematically evaluated in a comprehensive set of possible health outcomes. Here, we used the US Department of Veterans Affairs ...
新型的糖尿病治疗药物GLP-1受体激动剂,又迎来一个里程碑时刻。 近日,由Aditi R. Saxena领衔的研究团队,在著名期刊《自然·医学》发表全球首个口服小分子GLP-1受体激动剂(danuglipron)的重要临床研究数据[1]。 研究结果表明, danuglipron能显著降低2型糖尿病(T2DM)患者空腹血糖、餐后血糖及HbA1c水平,同时减轻...
图3.GLP-1改善多种动脉粥样硬化的危险因素 3.GLP-1RA抑制动脉粥样硬化的机制 动脉粥样硬化的形成和进展是一个复杂的过程,在血管内皮受损的基础上,循环中的低密度脂蛋白(LDL)颗粒从血管腔被运输到血管壁,在细胞外基质中聚积,从而更容易发生氧化,巨噬细胞和平滑肌细胞吞噬脂质后形成泡沫细胞,促进动脉粥样硬化斑块的形...